

EPI-00672

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jonathan W. Nyce

: Art Unit: 1635

Serial No.: 09/093,972

: Examiner: Dr. Janet Epps

Filed: June 9, 1998

: Appl. Ref. No.: EPI-00672

For:

**COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION & TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH BRONCHOCONSTRICTION, ALLERGY(IES) & INFLAMMATION**

**INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington D. C. 20231

Sir/Madam:


Pursuant to 37 C.F.R. §§ 1.97 and 1.98 and to the duty of disclosure set forth in 37 C.F.R. § 1.56, the examiner is requested to make of record the enclosed European Supplementary Search Report of January 17, 2002 and the references cited therein, which are listed on the PTO 1449 submitted herewith. A copy of each of the listed references is also enclosed. An Information Disclosure Statement has previously been submitted and considered by the examiner in this case.

Although the information submitted herewith may be "material" to the examiner's consideration of the subject application, this submission is not intended to constitute an admission that such information is "prior art" as to the claimed invention. Moreover, in accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

Less than three months have elapsed since the date of issuance of the Search Report in the corresponding European patent application No. 00919668. No fee is believed due for the submission of the IDS, however, the Assistant Commissioner for Patents is hereby authorized to charge the necessary fee to PTO Deposit Account No. 50-1728.

Respectfully submitted,

EpiGenesis Pharmaceuticals, Inc.

  
Viviana Amzel, Ph.D.

Reg. No. 30,930

Attorney for Applicant

March 6, 2002

Date

7 Clarke Drive  
Cranbury, NJ 08512  
Phone 609-409-3035  
Fax 609-860-8069  
Email VAmzel@epigene.com

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents Washington, D.C. 20231, on March 6, 2002, by Katsunori Ebata.

  
Signature

[illegible]

FOREIGN PATENT DOCUMENTS														
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
		9	6	4	0	1	6	2	12/19/96	WO	A61K	31/70		
		9	3	1	0	8	2	0	06/10/93	WO	A61K	48/00		
		9	8	1	1	2	1	1	03/19/98	WO	C12N	15/11		
		9	4	0	2	6	0	5	02/03/94	WO	C12N	15/12		
		9	8	2	3	2	9	4	06/04/98	WO	A61K	48/00		
		9	6	4	0	2	6	6	12/19/96	WO	A61K	48/00		
		9	3	1	2	7	5	6	07/08/93	WO	A61K			
		9	9	6	0	1	6	6	11/25/99	WO	C12Q	1/68		
		0	0	0	9	5	2	5	02/24/00	WO	C07H			

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	<p>Rahman, M. Sayeedur, et al., "Nebularine (9-2'-deoxy-beta-D-ribofuranosylpurine) has the template characteristics of adenosine in vivo and in vitro", Mutation Research, vol. 377, no. 2, 1997, pages 263-268</p> <p>Loakes, D. et al., "5-Nitroindole as an universal base analogue", Nucleic Acids Research, vol. 22, no. 20, 1994, pages 4039-4043</p>
	<p>Ohtsuka, E. et al., "An alternative approach to deoxyligonucleotides as hybridization probes by insertion of deoxynosine at ambiguous codon positions", Journal of Biological Chemistry, vol. 260, no. 5, 10 March 1985 (1985-03-10), pages 2605-2608</p> <p>Nichols, R. et al., "A universal nucleoside for use at ambiguous sites in DNA primers", NATURE, vol. 369, no. 6480, 9 June 1994 (1994-06-09), pages 492-493</p>
	<p>Metzger W. James et al., "Oligonucleotide therapy of allergic asthma", Journal of Allergy and Clinical Immunology, vol. 104, no. 2 part 1, August 1999 (1999-08), pages 260-266</p>

EXAMINER	DATE CONSIDERED
<p><b>*EXAMINER:</b> INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>	